Lurasidone

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

Retrieved on: 
Monday, May 22, 2023

CUPERTINO, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023 annual meeting took place in St. Louis, Missouri, USA, May 18-21, 2023. The ASPET posters are available at revivapharma.com/publications. Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.

Key Points: 
  • Brilaroxazine is currently in phase 3 clinical trials for schizophrenia and topline data from the pivotal phase 3 is anticipated in mid this year.
  • “These data support the concomitant use of brilaroxazine with other medications metabolized by CYP3A4 as most schizophrenia patients take multiple concomitant medications.
  • As part of the required clinical studies for New Drug Application (NDA), the drug-drug interactions between brilaroxazine with a strong CYP3A4 inhibitor (itraconazole) and inducer (phenytoin) were evaluated.
  • Brilaroxazine single dose co-administered with phenytoin at steady-state resulted in decrease of ~33%, 57% and 54% in brilaroxazine Cmax, AUC0-t, and AUC0∞, respectively.

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression

Retrieved on: 
Tuesday, February 21, 2023

DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.

Key Points: 
  • DURHAM, N.C., Feb. 21, 2023 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Lurasidone HCL tablets to its line of generic drugs.
  • Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents.
  • "A generic option in mental health treatment provides more accessible healthcare to those who are in need."
  • Adverse reactions 2 of lurasidone for treatment of schizophrenia and bipolar depression include somnolence, akathisia, which is a feeling of restlessness, anxiety, and/or agitation, and extrapyramidal symptoms.

NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022

Retrieved on: 
Thursday, November 10, 2022

RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022. The company will host a conference call and webcast on November 14, 2022, 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period.

Key Points: 
  • --Company to Host Conference Call November 14, 2022, at 8:00AM ET---
    RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ --NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.
  • NRx Pharmaceuticals to Host Conference Call & Webcast November 14, 2022, at 8:00 AM ET
    A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call.
  • NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022 or early Q1/2023.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022

RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company's business at the H.C. Wainwright & Co. 24th Annual Global Investment Conference.

Key Points: 
  • The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT).
  • Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect.
  • NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Retrieved on: 
Wednesday, July 13, 2022

National Science Board Presidential Appointee, 2018-2024

Key Points: 
  • National Science Board Presidential Appointee, 2018-2024
    RADNOR, Pa., July 13, 2022 /PRNewswire/ --NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, today announcedthe appointment of Stephen Willard, as its Chief Executive Officer ("CEO") and a member of the Company's Board of Directors.
  • The Company's interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer.
  • @NRXP Board Appoints BioPharma Veteran and National Science Board Presidential Appointee to Lead NRx Pharmaceuticals, Inc.
    "We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals' current needs.
  • This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S.

Sandoz Canada expands its generics portfolio with three new products

Retrieved on: 
Tuesday, July 5, 2022

During the spring, Sandoz Canada has launched the following three products.

Key Points: 
  • During the spring, Sandoz Canada has launched the following three products.
  • PrSandoz Teriflunomide is the third multiple sclerosis treatment in the companys portfolio, following the launch of Sandoz Fingolimod in November 2019 and Sandoz Dimethyl Fumarate in October 2021.
  • We are very proud of these additions to the Sandoz Canada portfolio, says Michel Robidoux, President and General Manager of Sandoz Canada.
  • Sandoz International GmbH is a world leader in generics and biosimilars and a division of the Swiss multinational Novartis.

NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

Retrieved on: 
Thursday, May 12, 2022

NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization).

Key Points: 
  • NRx Pharmaceuticals, Inc., enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality (not requiring hospitalization).
  • NRx Pharmaceuticals plans to start an NRX-101 Phase IIb/III registrational trial in patients with bipolar depression and acute suicidal ideation and behavior (ASIB) (requiring hospitalization) later this year.
  • In the second half of this year, NRx Pharmaceuticals expects to initiate a Phase IIb/III registrational trial in patients with bipolar depression and acute suicidal ideation and behavior (ASIB), which requires hospitalization of the patient.
  • NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals" or the "Company") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients.

PHARMASCIENCE INC. LAUNCHES PMS-LURASIDONE FOR THE TREATMENT OF THE SYMPTOMS OF SCHIZOPHRENIA AND SYMPTOMS OF DEPRESSION ASSOCIATED WITH BIPOLAR DISORDER

Retrieved on: 
Tuesday, May 3, 2022

Pms-LURASIDONE is indicated as monotherapy for the management of the manifestations of schizophrenia in adults and in adolescents (15-17 years of age).

Key Points: 
  • Pms-LURASIDONE is indicated as monotherapy for the management of the manifestations of schizophrenia in adults and in adolescents (15-17 years of age).
  • It is also indicated for the acute management of depressive episodes associated with bipolar disorder in adults and adolescents (13-17 years of age).
  • Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal.
  • Pharmascience Inc. has strong values based on the importance of investing in its employees and young people.

Global Bipolar Depression Market Insight, Epidemiology and Market Forecast 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021

The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Bipolar Depression - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Bipolar Depression epidemiology division provides insights about the historical and current Bipolar Depression patient pool and forecasted trends for every seven major countries.
  • In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression.

Angelini Pharma and Sunovion Pharmaceutical Europe receive EMA approval for Latuda, first Atypical Antipsychotic for the Treatment of Adolescent Schizophrenia in patients starting from 13 years of age

Retrieved on: 
Thursday, November 12, 2020

ROME, Nov. 12, 2020 /PRNewswire/ -- Angelini Pharma and Sunovion Pharmaceutical Europe announced today the European Medicines Agency (EMA) approval for Latuda (lurasidone), with the indication for the treatment of Adolescent Schizophrenia in patients starting from 13 years of age.

Key Points: 
  • ROME, Nov. 12, 2020 /PRNewswire/ -- Angelini Pharma and Sunovion Pharmaceutical Europe announced today the European Medicines Agency (EMA) approval for Latuda (lurasidone), with the indication for the treatment of Adolescent Schizophrenia in patients starting from 13 years of age.
  • Latuda becomes the first 2nd generation antipsychotic to be approved for patients suffering from schizophrenia as young as 13 years of age.
  • Latuda was first approved in Europe in 2013 for the treatment of adults (18 years and over) suffering from schizophrenia.
  • For further information, please visit www.angelinipharma.com
    Angelini Pharma and Sumitomo Dainippon Pharma are in partnership for the Commercialization of Latuda in Europe.